Review ArticleInternational Journal of Basic & Clinical Pharmacology
Publication: Role of myeloid growth factors in chemotherapy induced neutropenia
Int J Basic Clin Pharmacol. 2016;5(5):1715-1721.DOI10.18203/2319-2003.ijbcp20163205
Abstract
Neutropenia is a major dose limiting toxicity of many chemo therapeutic regimens. Haemopoietic colony - stimulating factors (CSFs) have been shown to reduce the duration and severity of chemotherapy induced neutropenia (CIN) and risk of febrile neutropenia. Supportive care with myeloid growth factors improve chemotherapy delivery by minimizing chemotherapy dose reductions or treatment delays by enabling the delivery of full dose chemotherapy (dose dense) in short time intervals. The goal of this article is to give comprehensive review of current literature regarding medical practice guidelines and risk assessment models for appropriate use of myeloid growth factors and management of febrile neutropenia.
Keywords
Affiliations
- Department of Radiation Oncology, MNJ Institute of Oncology and Regional Cancer Centre/Osmania Medical College, Hyderabad, India
- Department of Clinical Pharmacology and Therapeutics Nizam’s Institute of Medical Sciences, Punjagutta, Hyderabad, India
